onsdag 15 april 2015

Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: A pilot trial

http://www.biomedcentral.com/content/pdf/1743-7075-8-54.pdf

Conclusions: 
"These pilot data suggest that a Ketogenic Diet is suitable for even advanced cancer patients. It has no severe side effects and might improve aspects of quality of life and blood parameters in some patients  with advanced metastatic tumors."

Schmidt et al.: Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: A pilot trial. Nutrition & Metabolism 2011 8:54

BMC Cancer | Full text | Growth of human gastric cancer cells in nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and medium-chain triglycerides

http://www.biomedcentral.com/1471-2407/8/122


Abstract

Background
Among the most prominent metabolic alterations in cancer cells are the increase in glucose consumption and the conversion of glucose to lactic acid via the reduction of pyruvate even in the presence of oxygen. This phenomenon, known as aerobic glycolysis or the Warburg effect, may provide a rationale for therapeutic strategies that inhibit tumour growth by administration of a ketogenic diet with average protein but low in carbohydrates and high in fat enriched with omega-3 fatty acids and medium-chain triglycerides (MCT).
Methods
Twenty-four female NMRI nude mice were injected subcutaneously with tumour cells of the gastric adenocarcinoma cell line 23132/87. The animals were then randomly split into two feeding groups and fed either a ketogenic diet (KD group; n = 12) or a standard diet (SD group; n = 12) ad libitum. Experiments were ended upon attainment of the target tumor volume of 600 mm3 to 700 mm3. The two diets were compared based on tumour growth and survival time (interval between tumour cell injection and attainment of target tumour volume).
Results
The ketogenic diet was well accepted by the KD mice. The tumour growth in the KD group was significantly delayed compared to that in the SD group. Tumours in the KD group reached the target tumour volume at 34.2 ± 8.5 days versus only 23.3 ± 3.9 days in the SD group. After day 20, tumours in the KD group grew faster although the differences in mean tumour growth continued significantly. Importantly, they revealed significantly larger necrotic areas than tumours of the SD group and the areas with vital tumour cells appear to have had fewer vessels than tumours of the SD group. Viable tumour cells in the border zone surrounding the necrotic areas of tumours of both groups exhibited a glycolytic phenotype with expression of glucose transporter-1 and transketolase-like 1 enzyme.
Conclusion
Application of an unrestricted ketogenic diet enriched with omega-3 fatty acids and MCT delayed tumour growth in a mouse xenograft model. Further studies are needed to address the impact of this diet on other tumour-relevant functions such as invasive growth and metastasis.

PLOS ONE: The Ketogenic Diet and Hyperbaric Oxygen Therapy Prolong Survival in Mice with Systemic Metastatic Cancer

http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0065522

Ketogenic Diet and HBO2T produce significant anti-cancer effects when combined in a natural model of systemic metastatic cancer. Our evidence suggests that these therapies should be further investigated as potential non-toxic treatments or adjuvant therapies to standard care for patients with systemic metastatic disease.

Targeting insulin inhibition as a metabolic therapy in advanced cancer: A pilot safety and feasibility dietary trial in 10 patients - Nutrition

http://www.nutritionjrnl.com/article/S0899-9007(12)00186-4/abstract

Conclusion:
"Preliminary data demonstrate that an insulin-inhibiting diet is safe and feasible in selected patients with advanced cancer. The extent of ketosis, but not calorie deficit or weight loss, correlated with stable disease or partial remission. Further study is needed to assess insulin inhibition as complementary to
standard cytotoxic and endocrine therapies."

Targeting insulin inhibition as a metabolic therapy in advanced cancer: A pilot safety and feasibility dietary trial in 10 patients

Fine, Eugene J. et al.
Nutrition , Volume 28 , Issue 10 , 1028 - 1035

A Low Carbohydrate, High Protein Diet Slows Tumor Growth and Prevents Cancer Initiation

http://cancerres.aacrjournals.org/content/71/13/4484.short

Taken together, our findings offer a compelling preclinical illustration of the ability of a low CHO diet in not only restricting weight gain but also cancer development and progression.


Is the restricted ketogenic diet a viable alternative to the standard of care for managing malignant brain cancer?

http://www.sciencedirect.com/science/article/pii/S0920121111002063

"Targeting Cancer Metabolism with Ketosis and Hyperbaric Oxygen" by Angela M. Poff

http://scholarcommons.usf.edu/etd/5294/

Ketogenic Diet in Advanced Cancer: A Pilot Feasibility and Safety Trial in the Veterans Affairs Cancer Patient Population

http://omicsgroup.org/journals/ketogenic-diet-in-advanced-cancer-a-pilot-feasibility-and-safety-trial-in-the-veterans-affairs-cancer-patient-population-2167-0870.1000149.pdf

Ketones and lactate “fuel” tumor growth and metastasis

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047616/


Drug-Drug/Drug-Excipient Compatibility Studies on Curcumin using Non-Thermal Methods

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3992969/

"Curcumin is a hydrophobic polyphenol isolated from dried rhizome of turmeric (Curcuma Longa Linn & zingiberaceae family), which is responsible for various pharmacological activities including anti-cancer, anti-oxidant, anti-bacterial, anti-fungal, anti-viral and anti-inflammatory and expected to have medicinal benefits in arthritis, psoriasis, diabetes, acquired immunodeficiency syndrome, cardiovascular diseases, multiple sclerosis, cancer and lung fibrosis.1,2 However, clinical usefulness of curcumin in the treatment of cancer is limited due to poor aqueous solubility, hydrolytic degradation in alkaline pH, metabolism via glucuronidation and sulfation in the liver and in intestine, and poor oral bioavailability."

Chidambaram M, Krishnasamy K. Drug-Drug/Drug-Excipient Compatibility Studies on Curcumin using Non-Thermal Methods. Advanced Pharmaceutical Bulletin. 2014;4(3):309-312. doi:10.5681/apb.2014.045.

Piperine potentiates the hypocholesterolemic effect of curcumin in rats fed on a high fat diet

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061201/




Targeting cancer stem cells by curcumin and clinical applications. - PubMed - NCBI

http://www.ncbi.nlm.nih.gov/pubmed/24463298

Curcumin is a well-known dietary polyphenol derived from the rhizomes of turmeric, an Indian spice. The anticancer effect of curcumin has been demonstrated in many cell and animal studies, and recent research has shown that curcumin can target cancer stem cells (CSCs).







Curcumin, a promising anti-cancer therapeutic: a review of its chemical properties, bioactivity and approaches to cancer cell delivery - RSC Advances (RSC Publishing)

http://pubs.rsc.org/en/content/articlelanding/2014/ra/c3ra46396f#!divAbstract



The development of new anti-cancer treatments with greater efficacy and fewer side effects remains a significant challenge of modern scientific and medical research. Curcumin, a natural polyphenol found in the dietary spice turmeric, has been demonstrated to inhibit cancer cell survival and proliferation, and to induce apoptosis without promoting the development of side effects. However, due to its sparing solubility and low bioavailability, curcumin has not yet been clinically used to treat cancer.